<DOC>
	<DOCNO>NCT01349296</DOCNO>
	<brief_summary>BIBF1120 RAD001 solid tumor</brief_summary>
	<brief_title>BIBF 1120 RAD001 Solid Tumors - Phase I</brief_title>
	<detailed_description>A phase I trial evaluate safety tolerability combine BIBF 1120 RAD001 solid tumor determine maximum tolerate dose ( MTD ) combination</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Nintedanib</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>1 . Histologically cytologically proven solid tumor disease failure standard therapy regimen ( ) 2 . Age &gt; 18 year . 3 . ECOG performance status 0 1 . 4 . Life expectancy least 12 week . 5 . Subjects least one measurable ( CT MRI ) lesion . 6 . Adequate bone marrow , liver renal function assess follow laboratory requirement conduct within 7 day prior screen : Hemoglobin &gt; 9.0 g/dl Absolute neutrophil count ( ANC ) &gt; 1,500/mm3 Platelet count ³ 100,000/μl Total bilirubin within normal limit ALT AST &lt; 1.5 x upper limit normal ( &lt; 2.5 x upper limit normal patient liver involvement ) PTINR/PTT &lt; 1.5 x upper limit normal [ Patients therapeutically anticoagulated agent coumadin heparin allow participate provide prior evidence underlie abnormality parameter exist . ] Serum creatinine &lt; 1.5 x upper limit normal creatinine clearance ( CrCl ) ≥ 50 ml/min calculate either CockcroftGault 24 hour urine collection 7 . More 14 day since previous chemotherapy , radiotherapy surgery 8 . Negative urine serum HCG woman childbearing potential 9 . Signed date informed consent start specific protocol procedure 1 . Limited number prior line treatment ( include surgery radiotherapy , part standard therapy respective tumor entity ) 2 . Prior treatment BIBF 1120 VEGFR inhibitor ( bevacizumab allow ) 3 . Prior treatment RAD001 mTOR inhibitor 4 . Known hypersensitivity trial drug , excipients contrast medium 5 . Chemo , hormono , radio ( except brain extremity ) immunotherapy therapy monoclonal antibody small tyrosine kinase inhibitor within past 2 week prior treatment trial drug 6 . Persistence clinically relevant therapy relate toxicity previous chemo and/or radiotherapy 7 . Active brain metastasis ( e.g . stable &lt; 4 week , adequate previous treatment radiotherapy , symptomatic , require treatment anticonvulsant ; dexamethasone therapy allow administer stable dose least one month trial drug administration ) leptomeningeal metastasis ( document lumbar puncture ) 8 . History cardiac disease : congestive heart failure &gt; NYHA class 2 ; active coronary artery disease ( CAD ) , ( MI 6 mo prior study entry allow ) ; cardiac arrhythmia require antiarrhythmic therapy ( beta blocker digoxin permit ) uncontrolled hypertension 9 . Impairment gastrointestinal function gastrointestinal disease may significantly alter absorption BIBF1120 RAD001 ( e.g . ulcerative disease , uncontrolled nausea , vomit , diarrhea , malabsorption syndrome small bowel resection ) 10 . History HIV infection previously seropositive virus 11 . History Hepatitis B or/and C previously seropositive Hepatitis B or/and C virus 12 . Radiographic evidence cavitary necrotic tumor 13 . Centrally locate tumor radiographic evidence ( CT MRI ) local invasion major blood vessel 14 . Treatment investigational drug treatment another clinical trial within past 30 day start therapy concomitantly trial 15 . Patients seizure disorder require enzymeinducing antiepileptic 16 . Therapeutic anticoagulation ( except lowdose heparin and/or heparin flush need maintenance indwell intravenous devise ) antiplatelet therapy ( except lowdose therapy acetylsalicylic acid ≤325mg per day ) 17 . Major injury within past 10 day prior start study treatment incomplete wound heal and/or plan surgery ontreatment study period 18 . Evidence history bleed diasthesis thrombosis , know inherited predisposition bleed thrombosis 19 . Proteinuria CTC AE grade 2 great 20 . Active serious infection 21 . Patients undergoing renal dialysis 22 . Previous concurrent cancer distinct primary site histology cancer evaluate study EXCEPT cervical carcinoma situ , treat basal cell carcinoma , superficial bladder tumor [ Ta , Tis &amp; T1 ] cancer curatively treat &gt; 3 year prior study entry 23 . Serious illness concomitant nononcological disease neurologic , psychiatric , infectious disease active ulcer ( gastrointestinal tract , skin ) laboratory abnormality may increase risk associate study participation study drug administration judgment investigator would make patient inappropriate entry study 24 . Patients sexually active unwilling use medically acceptable method contraception ( e.g . implant , injectables , combine oral contraceptive , intrauterine device vasectomize partner participate female , condom participate male ) trial least three month end active therapy 25 . Pregnancy breast feed 26 . Psychological , familial , sociological geographical factor potentially hamper compliance study protocol followup schedule 27 . Active alcohol drug abuse</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Solid Tumors</keyword>
</DOC>